Phase Ia trial of SYN 004 in healthy volunteers as a potential therapy for the prevention of Clostridium difficile infection, antibacterial-associated diarrhoea and secondary antibacterial-resistant infections in patients receiving intravenous beta-lactam antibacterial therapy

Trial Profile

Phase Ia trial of SYN 004 in healthy volunteers as a potential therapy for the prevention of Clostridium difficile infection, antibacterial-associated diarrhoea and secondary antibacterial-resistant infections in patients receiving intravenous beta-lactam antibacterial therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Ribaxamase (Primary)
  • Indications Bacterial infections; Clostridium infections; Diarrhoea
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Synthetic Biologics
  • Most Recent Events

    • 09 Jun 2016 Results of two phase I studies published in the Clinical Drug Investigation.
    • 19 Nov 2015 According to a Synthetic Biologics media release, clinical updates from this trial will be presented at the Microbiome Clinical Program Seminar to be hosted by the company on December 10, 2015.
    • 03 Jun 2015 According to a Synthetic Biologics media release, data from this study were presented at the 115th General Meeting of the American Society of Microbiology (ASM2015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top